Clinical Trials
21 trialsNCT01220583 2026-05-27
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
Phase 2 Active not recruiting
NCT03180502 2026-05-26
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT02186847 2026-05-22
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT02254278 2026-05-22
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NRG Oncology
Phase 2 Completed
NCT02316548 2026-05-22
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Phase 2 Terminated
NCT02710734 2026-05-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Completed
NCT00593840 2026-05-19
Phase II Trial Evaluating Elimination of Radiation Therapy
Washington University School of Medicine
Phase 2 Active not recruiting
NCT00544830 2026-05-15
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02734537 2026-05-15
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT00715611 2026-05-14
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04165772 2026-05-13
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04369937 2026-05-13
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT04774419 2026-05-13
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04929028 2026-05-13
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05541016 2026-05-12
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Mayo Clinic
Phase 2 Recruiting
NCT02296684 2026-05-08
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Completed
NCT04671667 2026-05-08
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03493425 2026-05-05
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT04166318 2026-05-05
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06368817 2026-05-04
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Children's Oncology Group
Phase 2 Recruiting
NCT06532279 2026-05-04
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting